The studies were undertaken at an independent research laboratory in the US with significant experience with visceral Leishmaniasis animal models. Dosages of 10mg/kg and 20mg/kg of iCo-009 were tested. In both cases, iCo-009 resulted in greater than 99% eradication of parasitic infection.
Andrew Rae, iCo’s president & CEO, said: “These results are exciting. The preclinical work in three distinct animal models to date provides iCo with mounting confidence in the program and its potential to fight not only visceral Leishmaniasis, but also systemic fungal infections in the developed world in human and animal health.”